Capricor Therapeutics enters the weekend with shorts firmly in control — the stock down 11% on the week, short interest at a multi-month peak, and the borrow market tightening faster than at any point in recent months.
The price action tells the clearest story. CAPR closed at $26.71 on June 5, down 4.4% on the day and 19% below where it traded a month ago. That follows the May earnings print, which wiped nearly 5% in a single session and extended to a 15.6% drawdown over the five days that followed. The move has been consistent and directional — this is not a stock bouncing around a range.
The short position is the engine behind that pressure. Short interest climbed to 25.1% of the free float as of June 4, up 4.7% on the week and nearly 20% higher than a month ago. That month-long build is the sharpest since the ORTEX observable window begins, and it leaves the ORTEX short score at 74.3 — the highest reading in the series and up from 68.9 just two weeks ago. Bears are not rotating out; they are adding. The borrow market offers one partial counterpoint: cost to borrow remains undemanding at 0.55%, up 8% on the week but still at a level that imposes almost no friction on new shorts. What has changed is availability, which tightened from roughly 350% in late May to 197% now — a 44% drop in seven days. At 197%, the lending pool remains adequate, but the direction of travel is notable. The 52-week low for availability is 0.06%, a reminder of how much tighter conditions have been historically; the current pace of tightening bears watching.
Options traders are not hedging into the slide — if anything, the opposite. The put/call ratio is running at 0.39, slightly below its 20-day average of 0.41 and near the lower end of recent readings. That is a mild call-skew that sits at odds with the scale of the short build and the price decline. It suggests options market participants are not piling into downside protection at current levels, even as short sellers continue to add. The divergence between bearish positioning in the stock-lending market and the relatively relaxed options setup is one of the more interesting tensions in the current CAPR setup.
Institutional ownership adds another layer of complexity. Suvretta Capital Management added nearly 2.9 million shares in Q1, making it the second-largest holder at 6.6% of shares. Tang Capital added 1.7 million shares in the same period. BlackRock reported a 571,000-share increase as recently as late May. Those are meaningful builds from identifiable institutions — not passive index flows. Set against them, Point72 trimmed 1 million shares in Q1. The insider register, last updated through May 1, shows a cluster of coordinated selling: the CFO and General Counsel each sold 25,000 shares at roughly $31.70 on May 1, a month after an unnamed director sold 53,735 shares at $31.03. All trades carried low significance scores, and all came above current prices. The stock has since fallen 16% from those levels.
Peers offered little insulation this week. NRIX fell 17.6% and VKTX dropped 13.1% — both correlated names in the clinical-stage biotech space — suggesting the selloff has a sector dimension alongside the CAPR-specific clinical setback flagged in the recent note on the Phase 2 trial miss. The next scheduled catalyst is the Q2 earnings call on August 6. Between now and then, the key variable is whether the pace of short-interest accumulation continues at its current rate or plateaus — the answer will likely depend on any interim clinical or regulatory updates from the Duchenne muscular dystrophy program.
See the live data behind this article on ORTEX.
Open CAPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
